McKesson reported a 5% increase in total revenues and a decrease of 1% in adjusted earnings per diluted share.
Key Takeaways
McKesson Corporation reported a 5% increase in total revenues to $70.2 billion for the second quarter of fiscal year 2023. Earnings per diluted share from continuing operations increased to $6.46, while adjusted earnings per diluted share decreased by 1% to $6.06. The company raised its full-year adjusted earnings per diluted share guidance.
Total revenues increased by 5% to $70.2 billion.
Earnings per diluted share from continuing operations increased by $4.75 to $6.46.
Adjusted Earnings per Diluted Share decreased 1% to $6.06.
Fiscal 2023 Adjusted Earnings per Diluted Share guidance range increased to $24.45 to $24.95.
McKesson raised fiscal 2023 Adjusted Earnings per Diluted Share guidance to $24.45 to $24.95 from the previous range of $23.95 to $24.65 to reflect operating business performance and increased contribution from the U.S. government's COVID-19 vaccine distribution, kitting, and storage programs and COVID-19 tests.
Positive Outlook
U.S. government’s COVID-19 vaccine distribution program: $0.60 to $0.70
U.S. government’s kitting, storage, and distribution of ancillary supplies program and COVID-19 tests: $1.00 to $1.10
Fiscal 2023 Adjusted Earnings per Diluted Share guidance indicates 11% to 14% forecasted growth compared to prior year, excluding the impacts of the above items from both fiscal 2023 guidance and fiscal 2022 results.
McKesson signed an agreement in principle to extend its pharmaceutical distribution partnership with CVS Health through June 2027.
McKesson continues to expand its differentiated oncology and biopharma businesses, further demonstrating meaningful progress against its company priorities.
Challenges Ahead
Net gains and losses associated with McKesson Ventures’ equity investments: Approximately ($0.15)
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Second-quarter Adjusted Earnings per Diluted Share was $6.06 compared to $6.15 a year ago, a decrease of 1%, driven by prior year net gains from McKesson Ventures' equity investments and lower contribution from the U.S. government's COVID-19 vaccine distribution, kitting, and storage programs and COVID-19 tests, partially offset by a lower share count.
Second-quarter Adjusted Earnings per Diluted Share included pre-tax net losses of approximately $3 million associated with McKesson Ventures' equity investments, compared to pre-tax net gains of approximately $97 million in the second-quarter of fiscal 2022.
Second-quarter revenues for Medical-Surgical Solutions Segment decreased by 9%, driven by lower sales of COVID-19 tests, partially offset by growth in the primary care business.
Second-quarter revenues for International Segment decreased by 25%, driven by the divestitures of McKesson's UK and Austrian businesses.